DOTANOC

Small molecule

TTurku University Hospital

DOTANOC is one of 31 small molecule programs targeting Pulmonary Sarcoidosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary SarcoidosisActive, not recruiting

Pulmonary SarcoidosisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Pulmonary Sarcoidosis

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Approved

1 2

Plaquenil

Alnylam Pharmaceuticals

Approved

1 3

Nicorette

Rayos

3 5

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 6

Myfortic

Novartis

Phase 3

1 7

Acthar

MMallinckrodt

Approved

2 8

Cellcept

Novartis

Phase 3

—9

Decadron

AAspen Global Incorporated

Phase 3

1 10

Tracleer

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pulmonary Sarcoidosis1 trial

Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis

Unknown status·TTurku University Hospital·Phase 2/3·NCT02824419·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DOTANOC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DOTANOC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DOTANOC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Turku University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: TTurku University Hospital

DOTANOC

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pulmonary Sarcoidosis1 trial

References

Drug Info

Quick Facts

Related News